Cargando…
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
BACKGROUND: Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had...
Autores principales: | Ding, Wu, Li, Zhian, Wang, Caiyun, Ruan, GuoDong, Chen, LuPing, Tu, Chuanjian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976281/ https://www.ncbi.nlm.nih.gov/pubmed/29768351 http://dx.doi.org/10.1097/MD.0000000000010746 |
Ejemplares similares
-
Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis
por: Ding, Wu, et al.
Publicado: (2018) -
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018) -
Dynamic changes in marital status and survival in women with breast cancer: a population-based study
por: Ding, Wu, et al.
Publicado: (2021) -
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020) -
Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)